Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
November is Lung Cancer Awareness Month — 2015
...Videos Coming This Month:
-Clinical Trial Spotlight: Identifying Lung Cancer Patients Who Respond to Ponatinib — featuring Dr. Ross Camidge
GRACE
No that wasn´t noted.
So what are ``Acetylenic heteroaryl compounds `` ?
Its a patent for 788? Hope we hear something from
Jaybe/Biomaven etc..
COMBINATION CANCER THERAPY OF WEE1 AND MTOR INHIBITORS
The instant invention relates to methods for the treatment of cancer by administering a combination of a WEE1 inhibitor and an mTOR inhibitor. In one embodiment, the WEE1 inhibitor is WEE1-1 or a pharmaceutically acceptable salt thereof, or WEE1-2 or a pharmaceutically acceptable salt thereof, and the mTOR inhibitor is ridaforolimus, everolimus, temsirolimus, a rapamycin-analog or a harmaceutically acceptable salt thereof.
Applicants: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue Rahway, New Jersey 07065-0907 (US).
SHUMWAY, Stuart [US/US]; (US) (US only).
BENITA, Yair [IL/IL]; (IL) (US only).
FELDMAN, Igor [US/US]; (US) (US only).
O'NEIL, Jennifer [US/US]; (US) (US only).
BLOECHER, Andrew [US/US]; (US) (US only).
ARIAD PHARMACEUTICALS, INC. [US/US]; 26 Landsdowne Street Cambridge, Massachusetts 02139 (US)
?
patentscope
A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis
nature.com
Retrospective Evaluation of CML Patients in the National Compassionate Program
This observational study aims at assessing the tolerability and safety profiles of Ponatinib, a drug used for Chronic Myeloid Leukemia patients who are Philadelphia positive. This drug is used during the chronic phase of the disease, according to the Italian national compassionate law 648/96.
clinicaltrials.gov
Management of Thrombosis Risk with Ponatinib and other TKIs for CML?
Filmed on location in New York during the Great Debates & Updates in Hematologic Malignancies 2015, this webcast is part of a series that focuses on controversial areas in the management of hematologic malignancies as nationally-recognized thought leaders take opposing sides on topics of clinical interest
youtube
Building value via regional licensing; global dealmakers get guidance on Japan
bioworld.com
U.S. Patent and Trademark Office Awards Patent for Phosphorus-Containing Compounds and Uses Thereof
Pharmaceutical Tue 05 May 2015
Alexandria, May 5 -- U.S. Patent and Trademark Office has awarded Ariad Pharmaceuticals a patent for phosphorus-containing compounds and uses thereof. Berstein David L, Rozamus Leonard W, Wang Yihan and Metcalf Iii Chester A developed the invention. The patent application number is 13/295,826. The International Patent Classifica..
Global IP News
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
nature.com
..All patient samples showed a varied degree of sensitivity to BCR-ABL1 inhibitors, with ponatinib being the only BCR-ABL1 inhibitor that was effective in all patient samples (Figure 2). The cells of patient 1 that had an E255K mutation were only sensitive to dasatinib and ponatinib and showed minimal or no effect to other BCR-ABL1 inhibitors (for example, imatinib and nilotinib). Patient 2 had a T315I mutation and hence the patient cells were resistant to all primary BCR-ABL1 inhibitors except ponatinib and axitinib. Cells derived from patient 3 (with no mutation affecting BCR-ABL) were highly sensitive to all BCR-ABL1 inhibitors and the drug response profile resembled that of the TKI-sensitive cell lines (EM-2 and K-562)..
Search for Ariad..
patentscope
thats crazy, when will they begin to cover?
On 15 January 2015, orphan designation (EU/3/14/1421) was granted by the European Commission to ARIAD Pharma Ltd, United Kingdom, for ponatinib hydrochloride for the treatment of gastrointestinal stromal tumours.
European Medicines Agency
pdf published 06/03/2015
More interesting abstracts to present on AACR Annual Meeting 2015
April 18 - 22, 2015
Presentation Title: Discovery of AP26113, a potent, orally active inhibitor of anaplastic lymphoma kinase and clinically relevant mutants
Presentation Title: The potent ALK inhibitor AP26113 can overcome mechanisms of resistance to first- and second-generation ALK TKIs in preclinical models
Presentation Title: Ponatinib demonstrates antitumor activity in RET- and FGFR-driven patient-derived xenografts
AACR abstract search
Epic:Phase 3 Trial of Ponatinib Compared with Imatinib in Newly Diagnosed Chronic Myeloid Leukemia
At ASH 2014, Dr. Jeffrey Lipton discussed his abstract on Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML).
Hey guys, cant search the board. Can someone please tell me if that is old stuff?
Phase II Front-line Treatment of Adult Affected of Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia (ALL) With Ponatinib. (LAL1811)
ClinicalTrials.gov
god bless her..
Iclusig TRx/NRx are 104/47, +28%/+52% wk/wk, in week 40 since the January re-launch
from dougheuring, Twitter
The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells
Published 30 October 2014
free pdf article, follow link:
source: Dovepress
great find, thx for sharing this Jayby / Jesspro.
A big step in the direction of partnership/approval in Japan?
We´ll see..
“We are now well positioned to complete pricing and reimbursement negotiations in Europe and to ensure that Iclusig is available to appropriate Philadelphia-chromosome positive leukaemia patients,”
said Jonathan E. Dickinson, general manager, ARIAD Pharmaceuticals (Europe). “The authorized indications and the favorable benefit-risk balance of Iclusig give healthcare providers the ability to optimize the use of Iclusig in patients with resistant or intolerant CML.”
Resistant mutations in CML and Ph+ALL – role of ponatinib
Published 20 October 2014
Article PDF
source?
Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial
Clinical Cancer Research
Conclusions: Our study provides proof-of-concept that inhibiting the IGF1R compensatory response to mTOR inhibition is feasible with promising clinical activity in heavily pretreated advanced cancer, particularly in ER+/high proliferative breast cancer.
Managing Resistance to Targeted Agents: The Future of NSCLC Therapy
The ASCO Post
Search for Ap26113 + Ponatinib
ESMO 2014 Programme Pdf
And a 2nd screenshot from ESMO programme
ESMO Programme PDF
i think we will get some information at the ESMO
16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy
September 04 - September 07, 2014 - Philadelphia, USA
Someone was there? Much to hear about ponatinib..
source: esh.org
Ponatinib: a third-generation inhibitor for the treatment of CML
CMLHope.Com
Rare Earth Prices Hitting Bottom:
Molycorp On The Road To Being Cash Flow Positive
Seeking Alpha
Why Ariad didn´t present on Citi 9th Annual Biotech Conference?
They are listed as confirmed (presenting companies)
Citi 9th Annual Biotech Conference
Ariad Pharmaceuticals Inc Submits Korean Patent Application for Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers
source: Global IP News
Treating lung cancer - doing things differently
source: youtube
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
Available online 14 August 2014
source: Cancer Cell
Ariad submits korean patents
source: global ip news
A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein
A High-Throughput Assay for Small Molecule Destabilizers of the KRAS Oncoprotein